A phase I randomized, single blind, controlled, single center study to evaluate the safety and immunogenicity of a dose range of glycoconjugate antigen vaccine of group B streptococcus [streptococcal B vaccine conjugate] in healthy women 18- 40 years of age.

Trial Profile

A phase I randomized, single blind, controlled, single center study to evaluate the safety and immunogenicity of a dose range of glycoconjugate antigen vaccine of group B streptococcus [streptococcal B vaccine conjugate] in healthy women 18- 40 years of age.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2011

At a glance

  • Drugs Streptococcal B vaccine conjugate (Primary)
  • Indications Streptococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 07 Dec 2011 Actual end date for extension trial (NCT01053767) is December 2010.
    • 07 Dec 2011 Actual end date for extension trial (NCT01053767) is December 2010.
    • 07 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov record (Extension trial: NCT01053767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top